Process of extracting TAXOL.RTM. from taxus cuspidata

Details Process of extracting TAXOL.RTM. from taxus cuspidata Process of extracting TAXOL.RTM. from taxus cuspidata

1998-05-08

2000-05-23

Trinh, Ba K.

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

549511, C07D30514

Patent

active

060667486

DESCRIPTION:

BRIEF SUMMARY
BACKGROUND OF THE INVENTION

1. Field of the Invention
The present invention relates generally to medicines and pharmaceutical products derived from plants, and specifically to a process of extracting TAXOL.RTM. from the leaves of taxus cuspidata plants.
2. Description of the Prior Art
TAXOL.RTM. (paclitaxel) is one of a class of drugs called taxanes. These types of drugs promote polymerization of tubulin and stabilize the structure of intracellular microtubules. This process has the effect of inhibiting the normal dynamic reorganization of the microtubules that is necessary for interphase and mitotic functions. Paclitaxel may also potentiate the cytotoxic effects of radiation.
The pharmacokinetics of paclitaxel vary considerably depending on the dosage and duration of infusion. Plasma concentrations of paclitaxel decline in a biphasic manner following injection. Increasing a 24-hour infusion from 135 mg/mL to 175 mg/mL increased Cmax by 87% while the area under the plasma concentration-time curve (AUC) remained constant. Increasing a 3-hour infusion increased Cmax by 68% and the AUC by 89%. With the 24-hour infusion of paclitaxel, the mean apparent volume of distribution in the steady state ranged from 227 to 688 L/m2, indicating extensive extravascular distribution or tissue binding. In vitro studies show that 89% to 98% of paclitaxel is bound to human serum proteins. Paclitaxel may undergo hepatic metabolism in humans. Studies have demonstrated extensive nonrenal clearance. The disposition of paclitaxel in patients with renal or hepatic dysfunction has not yet been determined.
In two studies of ovarian cancer patients receiving paclitaxel in doses of 135 mg/mL or 175 mg/mL, the response rates were 22% and 30%, respectively, with 6 complete and 18 partial responses among 92 patients. Duration of response was 7.2 and 7.5 months, respectively, with median survival rates of 8.1 months and 15.9 months. A Phase III study of 471 breast cancer patients receiving paclitaxel in doses of 135 mg/mL or 175 mg/mL infused over 3 hours indicated an overall response rate of 26%, with 17 complete and 99 partial responses. The median duration of response was 3.5 months, and the median survival time was 11.7 months.
TAXOL.RTM. should not be used for patients with hypersensitivity to polyoxyethylated castor oil (Cremaphor EL) or TAXOL.RTM.. Patients should be pretreated with corticosroids (e.g., dexamethasone and diphenhydramine) and H2-receptor antagonists (cimetidine or ranitidine.) Patients receiving concomitant ketaconazole should be treated with caution. Two percent of patients receiving Taxol have severe hypersensitivity reactions that are characterized by dyspnea, hypotension, angioedema, and generalized urticaria. One incident of progressive hypotension, possibly related to the use of TAXOL.RTM., resulted in the death of the patient. Other side effects include bone marrow suppression, abnormal ECG, peripheral neuropathy, myalgia and arthralgia, alopecia, injection site reaction, nausea, vomiting, diarrhea, and mucositis. Continuing safety surveillance has produced rare reports of hepatic necrosis, hepatic encephalopathy, phlebitis, and cellulitis. Available as a clear, colorless to slightly yellow, viscous solution, TAXOL.RTM. is packaged in single-dose vials containing 30 mg/5 mL. After dilution with a suitable parenteral fluid to 0.3 to 1.2 mg/mL, 135 mg/m2 paclitaxel is infused intravenously over 24 hours every 3 weeks for ovarian cancer. The dose level for breast cancer is 175 mg/mL, administered in the same manner. TAXOL.RTM. treatment should not be repeated until neutrophil and platelet counts return to 1500 cells/mm2 and 100,000 cells/mm2, respectively.
The National Cancer Institute performed research on TAXOL.RTM. in the 1960's, examining some 35,000 botanical species in search for plants that could yield cancer-inhibiting products. The cancer-inhibiting material extracted from the bark of Taxus Brevifolia was reported to have beneficial effects upon patients suffering from leukemia, lung cancer, and other t

REFERENCES:
patent: 5723635 (1998-03-01), Durand et al.
patent: 5736366 (1998-04-01), Margraff
patent: 5744333 (1998-04-01), Cociancich et al.

Affiliated with

Also associated with

Rating

Process of extracting TAXOL.RTM. from taxus cuspidata does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Process of extracting TAXOL.RTM. from taxus cuspidata, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process of extracting TAXOL.RTM. from taxus cuspidata will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1837913